Next Article in Journal
Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients
Previous Article in Journal
Acknowledgement to Reviewers of JPM in 2019
Open AccessArticle

Genetic Polymorphisms of Pharmacogenes among the Genetically Isolated Circassian Subpopulation from Jordan

1
Department of Applied Biological Sciences, Jordan University of Science and Technology, P.O. Box 3030, Irbid 22110, Jordan
2
Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid 22110, Jordan
3
Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, University of Jordan, Amman 11942, Jordan
4
College of Medicine, King Khalid University, Abha 61421, Saudi Arabia
5
Department of Biology and Biotechnology, Hashemite University, Zarqa 13133, Jordan
6
Radcliffe Institute for Advanced Studies, Harvard University, Cambridge, MA 02138, USA
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2020, 10(1), 2; https://doi.org/10.3390/jpm10010002
Received: 30 November 2019 / Revised: 21 December 2019 / Accepted: 30 December 2019 / Published: 6 January 2020
Several genetic variants have been identified that cause variation among different populations and even within individuals of a similar descent. This leads to interindividual variations in the optimal dose of the drug that is required to sustain the treatment efficiency. In this study, 56 single nucleotide polymorphisms (SNPs) within several pharmacogenes were analyzed in 128 unrelated subjects from a genetically isolated group of Circassian people living in Jordan. We also compared these variant distributions to other ethnic groups that are available at two databases (Genome 1000 and eXAC). Our results revealed that the distribution of allele frequencies within genes among Circassians in Jordan showed similarities and disparities when compared to other populations. This study provides a powerful base for clinically relevant SNPs to enhance medical research and future pharmacogenomic studies. Rare variants detected in isolated populations can significantly guide to novel loci involved in the development of clinically relevant traits. View Full-Text
Keywords: pharmacogenomics; VIP polymorphism; phase I enzymes; phase II enzymes; metabolizing pharmacogenomics; VIP polymorphism; phase I enzymes; phase II enzymes; metabolizing
MDPI and ACS Style

AL-Eitan, L.N.; Rababa’h, D.M.; Hakooz, N.M.; Alghamdi, M.A.; Dajani, R.B. Genetic Polymorphisms of Pharmacogenes among the Genetically Isolated Circassian Subpopulation from Jordan. J. Pers. Med. 2020, 10, 2.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop